Paulex Bio Announces Registration of Phase 1/2a Trial of PAL-119, an Oral Small Molecule Designed to Regenerate and Restore the Function of Insulin-Producing Beta Cells
Paulex Bio Announces Registration of Phase 1/2a Trial of PAL-119, an Oral Small Molecule Designed to Regenerate and Restore the Function of Insulin-Producing Beta Cells
PR Newswire
SAN DIEGO, Nov. 2, 2026
First-in-human study plans to enroll healthy volunteers and adults with Type 1 or Type 2 diabetes to evaluate PAL-119's safety and tolerability and explore its effects on the body's own insulin production
SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Paulex Bio Inc., a biopharmaceutical company focused on rebuilding the body's own insulin-producing capacity, today announced the registration of its Phase 1/2a first-in-human trial of PAL-119, an investigational oral small molecule designed to regenerate and restore the function of insulin-producing pancreatic beta cells. The study (NCT07901595) will evaluate PAL-119 in healthy volunteers and adults with Type 1 or Type 2 diabetes.
Loss and dysfunction of beta cells are central to both forms of diabetes. In Type 1 diabetes, an autoimmune attack destroys these cells. In Type 2 diabetes, declining beta cell function and mass compound the effects of insulin resistance. PAL-119 is designed to regenerate beta cells and restore their ability to produce insulin, potentially providing a disease-modifying therapy that addresses a central biological driver of both Type 1 and Type 2 diabetes.
"Paulex's vision is to make beta cell regeneration a foundation of diabetes treatment and, ultimately, provide a functional cure for Type 1 and Type 2 diabetes," said Miguel Sanjuan, Ph.D., Co-Founder, President and CEO of Paulex Bio. "Unlike current diabetes medicines, which can replace insulin, stimulate insulin secretion or address other aspects of diabetes, PAL-119 is designed to enable the body to rebuild its own insulin-producing capacity by regenerating beta cells and restoring their ability to respond to glucose. We are excited to launch this clinical program investigating PAL-119 as an important first step toward our ambition of introducing a potentially first-of-its-kind oral medicine that restores the body's ability to produce insulin and reduces the daily burden of living with the disease."
PAL-119 builds on research from the Icahn School of Medicine at Mount Sinai demonstrating in pre-clinical studies that adult human beta cells can be stimulated to regenerate. PAL-119 is designed to regenerate beta cells through the inhibition of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), an enzyme that acts as a natural brake on beta cell replication. Additionally, the oral small molecule has demonstrated the ability to enhance beta cell function by promoting protein kinase A (PKA) signaling, which supports glucose sensing and insulin secretion. These complementary, dual-action mechanisms offer the potential to both regenerate functional beta cells and restore the body's ability to produce insulin in response to glucose.
About the Phase 1/2a Trial
The randomized, multipart study plans to enroll participants at clinical sites in Australia. The Phase 1 portion in healthy volunteers will evaluate single ascending doses in up to six cohorts, multiple ascending doses in up to three cohorts, and the effect of food on PAL-119 exposure. The ascending-dose portions are blinded and placebo-controlled. The food-effect portion uses an open-label crossover design.
The Phase 2a portion includes separate randomized, double-blind, placebo-controlled studies in adults with Type 2 and Type 1 diabetes. Participants with Type 2 diabetes will receive one of two PAL-119 dose levels or placebo; participants with Type 1 diabetes will receive PAL-119 or placebo.
Safety and tolerability are the primary focus. Additional assessments include pharmacokinetics and changes in plasma C-peptide, a marker of endogenous insulin production, as well as serum insulin, fasting glucose and GLP-1 levels. These measures will help explore PAL-119's effects on beta cell regeneration and function and inform further development.
About PAL-119
PAL-119 is an investigational, dual-action oral small molecule designed to regenerate and restore the function of insulin-producing beta cells, with potential applications in Type 1 and Type 2 diabetes. Originating from research at the Icahn School of Medicine at Mount Sinai, PAL-119 is designed to increase beta cell numbers through DYRK1A inhibition and enhance beta cell function through PKA-associated signaling. PAL-119 was engineered with improved target selectivity and substantially reduced brain exposure compared with harmine.
About Paulex Bio
Paulex Bio Inc. is a biopharmaceutical company focused on changing the course of diabetes by addressing the biological cause of the disease. Its lead candidate, PAL-119, is an investigational oral small molecule designed to regenerate and restore the function of insulin-producing beta cells, with potential applications in Type 1 and Type 2 diabetes. Paulex holds exclusive worldwide rights from the Icahn School of Medicine at Mount Sinai to PAL-119 and related compounds, including composition-of-matter patent families. For more information, visit www.paulexbio.com.
Contacts
Tiberend Strategic Advisors, Inc.
Investor Relations
David Irish / Brooke Cooper
231-632-0002 / 862-274-1134
dirish@tiberend.com / bcooper@tiberend.com
Media Relations
Casey McDonald / Michelle Katsel
646-577-8520 / 201-790-3390
cmcdonald@tiberend.com / mkatsel@tiberend.com
SOURCE Paulex Bio Inc.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
This Once-Hot AI Stock Now Looks Deeply Undervalued
3 Stocks to Sell and 3 Stocks to Buy for November
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
5 Stocks to Buy Trading at Big Discounts
United States